Literature DB >> 7541551

The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension.

P Boyle1, P Napalkov.   

Abstract

Benign prostatic hyperplasia (BPH) and hypertension are highly prevalent, age-related disorders in men which place a considerable burden on healthcare resources worldwide. Evidence of pathological BPH can be found in over 80% of autopsies conducted in men over 70 years of age; around 40% of men aged 50-64 years have symptoms compatible with the disease. Population studies suggest that over 50% of people aged 65-74 years may be hypertensive, and that cardiovascular disease is a major cause of death worldwide. The continued ageing of the population means that more people are living to older ages; life expectancy for men is likely to exceed 80 years by the end of this century in some developed countries. While BPH and hypertension are apparently diverse disease processes, they have some features in common (e.g. underlying aetiology of the sympathetic nervous system). However, little else is known about any associations between the two or the frequency of concomitant disease. There are clearly opportunities for further epidemiologic studies and the development of preventive strategies aimed at the early detection and treatment of concomitant BPH and hypertension.

Entities:  

Mesh:

Year:  1995        PMID: 7541551

Source DB:  PubMed          Journal:  Scand J Urol Nephrol Suppl        ISSN: 0300-8886


  14 in total

Review 1.  Advances in the design and synthesis of prazosin derivatives over the last ten years.

Authors:  Andreas Desiniotis; Natasha Kyprianou
Journal:  Expert Opin Ther Targets       Date:  2011-12-13       Impact factor: 6.902

Review 2.  Common conditions of the aging male: erectile dysfunction, benign prostatic hyperplasia, cardiovascular disease and depression.

Authors:  L Zakaria; A G Anastasiadis; R Shabsigh
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 3.  Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia.

Authors:  J L Pool; R S Kirby
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

4.  Pathophysiology of overactive bladder and urge urinary incontinence.

Authors:  William D Steers
Journal:  Rev Urol       Date:  2002

Review 5.  Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective.

Authors:  L M Eri; K J Tveter
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

Review 6.  Treatment of benign prostatic hyperplasia in hypertensive men.

Authors:  William B White; Timothy Moon
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-04       Impact factor: 3.738

7.  Effects of α-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension.

Authors:  S H Lee; K K Park; S Y Mah; B H Chung
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-06-22       Impact factor: 5.554

Review 8.  Complications of cataract surgery in patients with BPH treated with alpha 1A-blockers.

Authors:  Slawomir Jan Teper; Dariusz Dobrowolski; Edward Wylegala
Journal:  Cent European J Urol       Date:  2011-06-02

9.  High-dose terazosin therapy (5mg) in Korean patients with lower urinary tract symptoms with or without concomitant hypertension: a prospective, open-label study.

Authors:  Cheol Kwak; Jeong Ki Lee; Ja Hyeon Ku
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

Review 10.  A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia.

Authors:  J C Nickel; S Sander; T D Moon
Journal:  Int J Clin Pract       Date:  2008-10       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.